Dr Reddy's Laboratories Long Term Debt 2010-2024 | RDY

Dr Reddy's Laboratories long term debt from 2010 to 2024. Long term debt can be defined as the sum of all long term debt fields.
  • Dr Reddy's Laboratories long term debt for the quarter ending September 30, 2024 was $0.088B, a 20.55% increase year-over-year.
  • Dr Reddy's Laboratories long term debt for 2024 was $0.072B, a 350% increase from 2023.
  • Dr Reddy's Laboratories long term debt for 2023 was $0.016B, a 78.95% decline from 2022.
  • Dr Reddy's Laboratories long term debt for 2022 was $0.076B, a 11.63% decline from 2021.
Dr Reddy's Laboratories Annual Long Term Debt
(Millions of US $)
2024 $72
2023 $16
2022 $76
2021 $86
2020 $17
2019 $318
2018 $385
2017 $84
2016 $161
2015 $230
2014 $346
2013 $232
2012 $321
2011 $118
2010 $120
2009 $
Dr Reddy's Laboratories Quarterly Long Term Debt
(Millions of US $)
2024-09-30 $88
2024-06-30 $75
2024-03-31 $72
2023-12-31 $74
2023-09-30 $73
2023-06-30 $60
2023-03-31 $16
2022-12-31 $18
2022-09-30 $22
2022-06-30 $24
2022-03-31 $76
2021-12-31 $81
2021-09-30 $81
2021-06-30 $83
2021-03-31 $86
2020-12-31 $89
2020-09-30 $91
2020-06-30 $90
2020-03-31 $17
2019-12-31 $17
2019-09-30 $216
2019-06-30 $242
2019-03-31 $318
2018-12-31 $355
2018-09-30 $380
2018-06-30 $381
2018-03-31 $385
2017-12-31 $383
2017-09-30 $382
2017-06-30 $380
2017-03-31 $84
2016-12-31 $84
2016-09-30 $160
2016-06-30 $161
2016-03-31 $161
2015-12-31 $162
2015-09-30 $162
2015-06-30 $190
2015-03-31 $230
2014-12-31 $261
2014-09-30 $289
2014-06-30 $320
2014-03-31 $346
2013-12-31 $371
2013-09-30 $401
2013-06-30 $233
2013-03-31 $232
2012-12-31 $320
2012-09-30 $318
2012-06-30 $313
2012-03-31 $321
2011-12-31 $317
2011-09-30 $108
2011-06-30 $119
2011-03-31 $118
2010-12-31 $5
2010-09-30 $51
2010-06-30 $91
2010-03-31 $120
2009-12-31 $150
2009-09-30 $173
2009-06-30 $191
2009-03-31 $199
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $11.978B $3.350B
Dr. Reddy's Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., the UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy's operates through three segments: Global Generics comprising unbranded prescription drugs along with over-the-counter drugs. It includes the operations of the company's biologics business. Pharmaceutical Services & Active Ingredients (PSAI) comprising active pharmaceutical ingredients (API) and custom pharmaceutical services. Proprietary Products and Others involving the new chemical entities, the differentiated formulations business and a dermatology specialty business. The company has a strategic partnership with Glaxo to market selected products across emerging markets outside India.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $19.044B 6.25
BridgeBio Pharma (BBIO) United States $4.260B 0.00
Bausch Health Cos (BHC) Canada $3.012B 2.18
Amphastar Pharmaceuticals (AMPH) United States $2.097B 12.61
Supernus Pharmaceuticals (SUPN) United States $1.962B 26.71
Taysha Gene Therapies (TSHA) United States $0.434B 30.29
Personalis (PSNL) United States $0.261B 0.00
Assembly Biosciences (ASMB) United States $0.098B 0.00
Sol-Gel Technologies (SLGL) Israel $0.012B 0.00
Evoke Pharma (EVOK) United States $0.007B 0.00
Teligent (TLGT) United States $0.000B 0.00